Observational Study of Males With Creatine Transporter Deficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-12-31

Study Completion Date

2022-10-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this study are to illustrate the clinical, neuro/electrophysiologic, biochemical, and developmental status and progression of patients with Creatine Transporter Deficiency (CTD) and to evaluate the utility of performance-based and other measures in the CTD population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relevant Outcome Measures for Creatine Transporter Deficiency Patient

NCT06018519

Creatine Transporter Defect

RECRUITING NA

Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis

NCT00004312

Cystinosis

COMPLETED

Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status

NCT01629940

X-linked Hypohidrotic Ectodermal Dysplasia Hypohidrotic Ectodermal Dysplasia

COMPLETED

Early Diagnosis Of Childhood Cerebral ALD

NCT02948062

Adrenoleukodystrophy

WITHDRAWN

Cardiac Outcome Measures in Children With Muscular Dystrophy

NCT01066455

Duchenne Muscular Dystrophy Becker Muscular Dystrophy Limb Girdle Muscular Dystrophy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational study designed to determine an appropriate clinical assessment battery for males with CTD, and to evaluate Magnetic resonance spectroscopy (MRS) along with other potential biomarkers. It is designed to explore developmental domains of interest and to examine the feasibility and utility of various neuropsychological assessments to measure domains of interest, and to identify possible endpoints for interventional studies. Study will also explore genotype-phenotype correlations.

Clinical adverse events will be monitored throughout the study.

This study was previously posted by Lumos Pharma, which has been transferred to Ultragenyx in June 2019.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Creatine Deficiency, X-linked

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject has genomic confirmation of a pathologic mutation in the SLC6A8 gene.
2. Subject is able to complete study-related procedures.
3. Subjects' parents/guardians/caregivers must provide written consent (informed consent) to study-related procedures, and if appropriate, the subject will provide an assent.

Exclusion Criteria

1. Subject has had status epilepticus within 3 months of screening.
2. Subject is unable to comply with the study procedures or with a clinical disease or laboratory abnormality that in the opinion of the investigator would potentially increase the risk of participation.

Minimum Eligible Age

6 Months

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No